From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Articles|July 12, 2022
Daily OTC Pearl: Instant Sleep
Author(s)Saro Arakelians, PharmD
Advertisement
OTC/Lifestyle Pearl of the Day: Instant Sleep
Indication: Instant Sleep is intended to aid with falling asleep faster and staying asleep longer.
Insight:
- Natural sleep aid contains a triple strength blend of herbal sleep support ingredients extracted from plants that have long been used to regulate sleep.
- L-theanine promotes both physical and mental relaxation.
- Melatonin helps to fall asleep and gives a high quality of rest better than you will find in any sleep supplement.
- Ingredients: L-Theanine, 5-HTP, melatonin, magnesium, mucuna pruriens extract, GABA, and phellodendron root (herb powder) that has many sleep support properties.
- Directions: Two capsules before bedtime with 8 oz of water.
Source:
Advertisement
Related to this article
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
3
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
4
Glucose Monitoring: Timing Makes Every Reading Count
5